{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:44:08Z","timestamp":1787021048594,"version":"build-2736575974"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:00:00Z","timestamp":1769212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"2023 Kindai University Research Environment Grant","award":["KD2304"],"award-info":[{"award-number":["KD2304"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharm Health Care Sci"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used for managing inflammatory disorders such as rheumatoid arthritis (RA); however, their long-term use is frequently associated with gastrointestinal (GI) complications, often leading to RA treatment discontinuation. To address this issue, we developed an oral formulation of troxipide (TRO), a pharmaceutical agent with gastroprotective properties, using nanosuspension technology to enhance its GI absorption and therapeutic efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The TRO nanosuspensions (TRO-NP@dis) were prepared by bead milling with methylcellulose (MC) as a stabilizing agent, yielding particles with an average diameter of 148\u00a0nm. An adjuvant-induced arthritis (AA) rat model, characterized by heightened susceptibility to NSAID-induced GI injury, was employed to assess pharmacokinetics and therapeutic efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>TRO-NP@dis showed improved dispersibility relative to conventional microparticle dispersions (TRO-MP@dis). Although the viscosities and zeta potentials of TRO-MP@dis and TRO-NP@dis were comparable, the solubility of TRO-NP@dis was markedly higher. Pharmacokinetic studies in rats revealed enhanced retention of TRO in the stomach, jejunum, and ileum following oral administration of TRO-NP@dis compared with TRO-MP@dis. Indomethacin (IND) administration (40\u00a0mg\/kg) significantly increased the mucosal lesion area in AA rats compared to that in controls. However, the co-administration of TRO-NP@dis significantly reduced the lesion areas in the stomach, jejunum, and ileum compared to those in vehicle-treated AA rats, indicating notable protective effects. These findings suggested that TRO-NP@dis confers enhanced mucosal adhesion and retention, leading to improved therapeutic outcomes in patients with IND-induced GI injury.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This nanosuspension-based delivery system represents a promising approach for mitigating NSAID-related GI complications in patients with RA by increasing local drug concentrations and reducing mucosal damage.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40780-026-00542-w","type":"journal-article","created":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T09:35:36Z","timestamp":1769247336000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Troxipide nanosuspensions prevent indomethacin\u2011induced gastrointestinal lesions in adjuvant-induced arthritis rats"],"prefix":"10.1186","volume":"12","author":[{"given":"Kazuya","family":"Fujimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Otake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rie","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiko","family":"Ogata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chika","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohito","family":"Kawasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Ishizaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kotake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriaki","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,24]]},"reference":[{"key":"542_CR1","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1046\/j.1365-2036.1999.00548.x","volume":"13","author":"S Kato","year":"1999","unstructured":"Kato S, Tanaka A, Kunikata T, Nishijima M, Takeuchi K. Changes in gastric mucosal ulcerogenic responses in rats with adjuvant arthritis: role of nitric oxide. Aliment Pharmacol Ther. 1999;13:833\u201340.","journal-title":"Aliment Pharmacol Ther"},{"key":"542_CR2","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1248\/yakushi.121.743","volume":"121","author":"S Kato","year":"2001","unstructured":"Kato S. Changes in ulcerogenic response to non-steroidal anti-inflammatory drugs (NSAIDs) in adjuvant arthritic rats. Yakugaku Zasshi. 2001;121:743\u201351.","journal-title":"Yakugaku Zasshi"},{"key":"542_CR3","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1007\/s10620-013-2606-0","volume":"58","author":"S Zhang","year":"2013","unstructured":"Zhang S, Qing Q, Bai Y, Mao H, Zhu W, Chen Q, et al. Rebamipide helps defend against nonsteroidal anti-inflammatory drugs induced gastroenteropathy: A systematic review and meta-analysis. Dig Dis Sci. 2013;58:1991\u20132000.","journal-title":"Dig Dis Sci"},{"key":"542_CR4","first-page":"878","volume":"50","author":"T Mine","year":"1991","unstructured":"Mine T, Kataoka A, Fujisaki J, Sato E, Yasuda H, Akimoto K, et al. Effects of cimetidine and Troxipide on gastric mucosal prostaglandin synthesis in patients with chronic gastric ulcer. Curr Ther Res. 1991;50:878\u201387.","journal-title":"Curr Ther Res"},{"key":"542_CR5","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S1590-8658(00)80023-7","volume":"32","author":"K Kusugami","year":"2000","unstructured":"Kusugami K, Ina K, Hosokawa T, Kobayashi F, kusajima H, momo K, et al. Troxipide, a novel antiulcer compound, has inhibitory effects on human neutrophil migration and activation induced by various stimulants. Dig Liver Dis. 2000;32:305\u201311.","journal-title":"Dig Liver Dis"},{"key":"542_CR6","first-page":"757","volume":"33","author":"M Inoue","year":"2005","unstructured":"Inoue M, Takahashi M, Ishibashi Y, Sueyoshi S, Kobayashi F, Matsuzawa S. Effects of Troxipide on the prednisolone-induced aggravation of gastric mucosal lesions occurred by HC1 in rats. Jpn Pharmacol Ther. 2005;33:757\u201363.","journal-title":"Jpn Pharmacol Ther"},{"issue":"2","key":"542_CR7","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1023\/A:1005656916830","volume":"46","author":"H Matsui","year":"2001","unstructured":"Matsui H, Murata Y, Kobayashi F, Shiba R, Momo K, Kondo Y, et al. Diclofenac-induced gastric mucosal fluorescence in rats. Dig Dis Sci. 2001;46(2):338\u201344.","journal-title":"Dig Dis Sci"},{"issue":"1","key":"542_CR8","first-page":"32","volume":"2","author":"A Chaudhary","year":"2012","unstructured":"Chaudhary A, Nagaich U, Gulati N, Sharma VK, Khosa RL, Partapur MU. Enhancement of solubilization and bioavailability of poorly soluble drugs by physical and chemical modifications: A recent review. J Adv Pharm Educ Res. 2012;2(1):32\u201367.","journal-title":"J Adv Pharm Educ Res"},{"key":"542_CR9","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.addr.2007.08.043","volume":"60","author":"JM Custodio","year":"2008","unstructured":"Custodio JM, Wu CY, Benet LZ. Predicting drug disposition, absorption \/elimination \/transporter interplay and the role of food on drug absorption. Adv Drug Deliv Rev. 2008;60:717\u201333.","journal-title":"Adv Drug Deliv Rev"},{"key":"542_CR10","first-page":"1955","volume":"11","author":"SR Hwang","year":"2014","unstructured":"Hwang SR, Byun Y. Advances in oral macromolecular drug delivery expert Opin. Drug Deliv. 2014;11:1955\u201367.","journal-title":"Drug Deliv"},{"key":"542_CR11","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.addr.2011.12.009","volume":"64","author":"LM Ensign","year":"2012","unstructured":"Ensign LM, Cone R, Hanes J. Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. Adv Drug Deliv Rev. 2012;64:557\u201370.","journal-title":"Adv Drug Deliv Rev"},{"key":"542_CR12","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.biotechadv.2014.07.006","volume":"32","author":"BF Choonara","year":"2014","unstructured":"Choonara BF, Choonara YE, Kumar P, Bijukumar D, du Toit LC, Pillay V. A review of advanced oral drug delivery technologies facilitating the protection and absorption of protein and peptide molecules. Biotechnol Adv. 2014;32:1269\u201382.","journal-title":"Biotechnol Adv"},{"key":"542_CR13","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.jcis.2015.10.057","volume":"463","author":"AR Neves","year":"2016","unstructured":"Neves AR, Queiroz JF, Lima SAC, Figueiredo F, Fernandes R, Reis S. Cellular uptake and transcytosis of lipid-based nanoparticles across the intestinal barrier: relevance for oral drug delivery. J Colloid Interface Sci. 2016;463:258\u201365.","journal-title":"J Colloid Interface Sci"},{"key":"542_CR14","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/nmat3776","volume":"12","author":"S Mura","year":"2013","unstructured":"Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nat Mater. 2013;12:991\u20131003.","journal-title":"Nat Mater"},{"key":"542_CR15","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ijpharm.2013.02.030","volume":"447","author":"J Renukuntla","year":"2013","unstructured":"Renukuntla J, Vadlapudi AD, Patel A, Boddu SH, Mitra AK. Approaches for enhancing oral bioavailability of peptides and proteins. Int J Pharm. 2013;447:75\u201393.","journal-title":"Int J Pharm"},{"key":"542_CR16","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.nantod.2017.08.006","volume":"16","author":"S Zhang","year":"2017","unstructured":"Zhang S, Langer R, Traverso G. Nanoparticulate drug delivery systems targeting inflammation for treatment of inflammatory bowel disease. Nano Today. 2017;16:82\u201396.","journal-title":"Nano Today"},{"key":"542_CR17","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.addr.2017.04.008","volume":"114","author":"JE Vela Ramirez","year":"2017","unstructured":"Vela Ramirez JE, Sharpe LA, Peppas NA. Current state and challenges in developing oral vaccines. Adv Drug Deliv Rev. 2017;114:116\u201331.","journal-title":"Adv Drug Deliv Rev"},{"key":"542_CR18","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/imr.12182","volume":"260","author":"T Pelaseyed","year":"2014","unstructured":"Pelaseyed T, Bergstrom JH, Gustafsson JK, Ermund A, Birchenough GM, Schutte A, et al. The mucus and mucins of the goblet cells and enterocytes provide the first defense line of the Gastrointestinal tract and interact with the immune system. Immunol Rev. 2014;260:8\u201320.","journal-title":"Immunol Rev"},{"key":"542_CR19","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1021\/mp100149j","volume":"7","author":"DM Mudie","year":"2010","unstructured":"Mudie DM, Amidon GL, Amidon GE. Physiological parameters for oral delivery and in vitro testing. Mol Pharm. 2010;7:1388\u2013405.","journal-title":"Mol Pharm"},{"key":"542_CR20","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s11095-012-0889-z","volume":"30","author":"L Gao","year":"2013","unstructured":"Gao L, Liu G, Ma J, Wang X, Zhou L, Li X, et al. Application of drug nanocrystal technologies on oral drug delivery of poorly soluble drugs. Pharm Res. 2013;30:307\u201324.","journal-title":"Pharm Res"},{"key":"542_CR21","doi-asserted-by":"publisher","first-page":"5343","DOI":"10.2147\/IJN.S317046","volume":"10","author":"H Otake","year":"2021","unstructured":"Otake H, Goto R, Ogata F, Isaka T, Kawasaki N, Kobayakawa S, et al. Fixed-Combination eye drops based on Fluorometholone nanoparticles and Bromfenac\/Levofloxacin solution improve drug corneal penetration. Int J Nanomed. 2021;10:5343\u201356.","journal-title":"Int J Nanomed"},{"key":"542_CR22","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.2147\/IJN.S196681","volume":"18","author":"N Nagai","year":"2019","unstructured":"Nagai N, Ogata F, Otake H, Nakazawa Y, Kawasaki N. Energy-dependent endocytosis is responsible for drug transcorneal penetration following the instillation of ophthalmic formulations containing indomethacin nanoparticles. Int J Nanomed. 2019;18:1213\u201327.","journal-title":"Int J Nanomed"},{"key":"542_CR23","doi-asserted-by":"publisher","first-page":"5685","DOI":"10.2147\/IJN.S430952","volume":"9","author":"S Masuda","year":"2023","unstructured":"Masuda S, Deguchi S, Ogata F, Yoshitomi J, Otake H, Kanai K, et al. Nasal absorption enhancement of Mometasone furoate nanocrystal dispersions. Int J Nanomed. 2023;9:5685\u201399.","journal-title":"Int J Nanomed"},{"key":"542_CR24","doi-asserted-by":"publisher","first-page":"4990","DOI":"10.3390\/ijms20204990","volume":"20","author":"N Nagai","year":"2019","unstructured":"Nagai N, Sakamoto R, Yamamoto S, Deguchi S, Otake H, Tanino T. Solid nanocrystals of rebamipide promote recovery from Indomethacin-Induced Gastrointestinal bleeding. Int J Mol Sci. 2019;20:4990.","journal-title":"Int J Mol Sci"},{"key":"542_CR25","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jconrel.2014.09.031","volume":"196","author":"VK Pawar","year":"2014","unstructured":"Pawar VK, Meher JG, Singh Y, Chaurasia M, Reddy BS, Chourasia MK. Targeting of Gastrointestinal tract for amended delivery of protein\/peptide therapeutics: strategies and industrial perspectives. J Control Release. 2014;196:168\u201383.","journal-title":"J Control Release"},{"key":"542_CR26","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1517\/17425247.2015.1018175","volume":"12","author":"EM Pridgen","year":"2015","unstructured":"Pridgen EM, Alexis F, Farokhzad OC. Polymeric nanoparticle drug delivery technologies for oral delivery applications. Expert Opin Drug Deliv. 2015;12:1459\u201373.","journal-title":"Expert Opin Drug Deliv"},{"key":"542_CR27","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.addr.2012.10.007","volume":"65","author":"Y Yun","year":"2013","unstructured":"Yun Y, Cho YW, Park K. Nanoparticles for oral delivery: targeted nanoparticles with peptidic ligands for oral protein delivery. Adv Drug Deliv Rev. 2013;65:822\u201332.","journal-title":"Adv Drug Deliv Rev"},{"key":"542_CR28","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.ijpharm.2009.07.005","volume":"380","author":"S Verma","year":"2009","unstructured":"Verma S, Gokhale R, Burgess DJ. A comparative study of top-down and bottom-up approaches for the Preparation of micro\/nanosuspensions. Int J Pharm. 2009;380:216\u201322.","journal-title":"Int J Pharm"},{"key":"542_CR29","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ijpharm.2008.07.023","volume":"364","author":"B Van Eerdenbrugh","year":"2008","unstructured":"Van Eerdenbrugh B, Van den Mooter G, Augustijns P. Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products. Int J Pharm. 2008;364:64\u201375.","journal-title":"Int J Pharm"},{"key":"542_CR30","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/0378-5173(95)00122-Y","volume":"125","author":"GG Liversidge","year":"1995","unstructured":"Liversidge GG, Cundy KC. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int J Pharm. 1995;125:91\u20137.","journal-title":"Int J Pharm"},{"key":"542_CR31","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.tox.2014.02.012","volume":"319","author":"N Nagai","year":"2014","unstructured":"Nagai N, Ito Y, Okamoto N, Shimomura Y. A nanoparticle formulation reduces the corneal toxicity of indomethacin eye drops and enhances its corneal permeability. Toxicology. 2014;319:53\u201362.","journal-title":"Toxicology"},{"key":"542_CR32","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1023\/A:1016212804288","volume":"12","author":"GL Amidon","year":"1995","unstructured":"Amidon GL, Lennern\u00e4s H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12:413\u201320.","journal-title":"Pharm Res"},{"key":"542_CR33","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1201\/9780585216157","volume-title":"Pharmaceutical Preformulation. Volume14","author":"JT Carstensen","year":"1998","unstructured":"Carstensen JT. Pharmaceutical Preformulation. Volume14. Lancaster: Technomic Publishing Company; 1998. p. 47."},{"key":"542_CR34","volume-title":"Martin\u2019s physical pharmacy and pharmaceutical sciences","author":"PJ Sinko","year":"2005","unstructured":"Sinko PJ. Martin\u2019s physical pharmacy and pharmaceutical sciences. Philadelphia: Lippincott Williams & Wilkins; 2005."},{"key":"542_CR35","volume-title":"Biopharmaceutics and pharmacokinetics: A treatise","author":"DM Brahmankar","year":"2005","unstructured":"Brahmankar DM, Jaiswal SB. Biopharmaceutics and pharmacokinetics: A treatise. Deihi: Vallabh Prakashan; 2005."},{"key":"542_CR36","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.ijpharm.2018.01.018","volume":"538","author":"J Griesser","year":"2018","unstructured":"Griesser J, Het\u00e9nyi G, Kadas H, Demarne F, Jannin V, Bernkop-Schn\u00fcrch A. Self-emulsifying peptide drug delivery systems: how to make them highly mucus permeating. Int J Pharm. 2018;538:159\u201366.","journal-title":"Int J Pharm"},{"key":"542_CR37","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1016\/S0006-3495(01)75844-4","volume":"81","author":"SS Olmsted","year":"2001","unstructured":"Olmsted SS, Padgett JL, Yudin AI, Whaley KJ, Moench TR, Cone RA. Diffusion of macromolecules and virus-like particles in human cervical mucus. Biophy J. 2001;81:1930\u201337.","journal-title":"Biophy J"},{"key":"542_CR38","doi-asserted-by":"publisher","first-page":"768","DOI":"10.3109\/1061186X.2015.1086359","volume":"23","author":"HM Yildiz","year":"2015","unstructured":"Yildiz HM, McKelvey CA, Marsac PJ, Carrier RL. Size selectivity of intestinal mucus to diffusing particulates is dependent on surface chemistry and exposure to lipids. J Drug Target. 2015;23:768\u201374.","journal-title":"J Drug Target"},{"key":"542_CR39","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/PL00000227","volume":"50","author":"S Sakuma","year":"2001","unstructured":"Sakuma S, Nishigaki F, Magari K, Ogawa T, Miyata S, Ohkubo Y, et al. FK506 is superior to methotrexate in therapeutic effects on advanced stage of rat adjuvant-induced arthritis. Inflamm Res. 2001;50:509\u201314.","journal-title":"Inflamm Res"},{"key":"542_CR40","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/0163-7258(83)90062-1","volume":"21","author":"ME Billingham","year":"1983","unstructured":"Billingham ME. Models of arthritis and the search for anti-arthritic drugs. Pharmacol Ther. 1983;21:389\u2013428.","journal-title":"Pharmacol Ther"}],"container-title":["Journal of Pharmaceutical Health Care and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40780-026-00542-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-026-00542-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-026-00542-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:05:21Z","timestamp":1781629521000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40780-026-00542-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,24]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["542"],"URL":"https:\/\/doi.org\/10.1186\/s40780-026-00542-w","relation":{},"ISSN":["2055-0294"],"issn-type":[{"value":"2055-0294","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,24]]},"assertion":[{"value":"1 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were performed in accordance with the guidelines of Kindai University, the Japanese Pharmacological Society, and NIH. The experimental protocols were approved on April 1, 2022, by Kindai University under the project identification code KAPS-2022-010, and the study was conducted in compliance with the ARRIVE and AVMA euthanasia guidelines 2020.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23"}}